Phase I Study of Preoperative Detection of Colorectal Carcinoma With Bispecific Antibody Pretargeting
- Assess the pharmacokinetics and tissue distribution of anti-CEA x anti-HSG bispecific
monoclonal antibody TF2 in patients with colorectal cancer.
OUTLINE: This is a multicenter study.
Patients receive iodine I 131-labeled anti-CEA x anti-HSG bispecific monoclonal antibody TF2
(^131I-TF2) IV over 10-20 minutes on day 1. Patients also undergo whole-body external
scintigraphy at various times during the study.
Blood samples are collected at baseline and periodically after ^131I-TF2 infusion for
pharmacokinetic studies and ^131I-TF2 biodistribution by ELISA and radioactivity
Masking: Open Label, Primary Purpose: Diagnostic
Aiwu R. He, MD
Lombardi Cancer Research Center
|Lombardi Comprehensive Cancer Center at Georgetown University Medical Center||Washington, District of Columbia 20007|